ARA-290, also studied under the name cibinetide, is an 11-amino-acid peptide derived from the structure of erythropoietin (EPO) — but engineered specifically to activate the innate repair receptor pathway without triggering EPO’s red-blood-cell-stimulating effects. That distinction is the entire point of the compound.
Why Split EPO’s Effects Apart at All
Erythropoietin has two separable biological roles: stimulating red blood cell production (its clinical use in anemia) and activating a separate tissue-protective, anti-inflammatory pathway through what researchers call the innate repair receptor. ARA-290 was designed to isolate the second effect while eliminating the first, avoiding the cardiovascular risk profile associated with elevated red blood cell counts.
Where the Research Has Focused
Clinical-stage research on cibinetide has centered on neuropathic pain and small-fiber neuropathy, including studies in sarcoidosis-associated neuropathy. In the broader research-peptide community, interest tends to track that same neuropathic and tissue-protective framing rather than the general recovery use cases associated with peptides like BPC-157.
An Important Distinction From Performance-Enhancing EPO Use
Because of its EPO lineage, ARA-290 sometimes gets lumped into performance-enhancement conversations. That’s a mischaracterization of the mechanism — the entire design goal was to strip out the erythropoietic (blood-cell-boosting) effect, which is the property performance contexts would actually be seeking.
Sourcing
ARA-290 is available for research purposes through the following vendor.